## Abstract One hundred and ninety two adults (median age 44 years) with __de novo__ or secondary (__n__ = 17) acute myelogenous leukemia (AML) were managed with a maximum of six intended courses with adriamycin 25 mg/m^2^/d for three days, plus cytarabine 200 mg/m^2^/d and 6βthioguanine 200 mg/m^2
Early consolidation chemotherapy for adults with acute leukemia in remission
β Scribed by Bodey, Gerald P. ;Rodriguez, Victorio ;McCredie, Kenneth B. ;Freireich, Emil J.
- Publisher
- John Wiley and Sons
- Year
- 1976
- Tongue
- English
- Weight
- 567 KB
- Volume
- 2
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Three courses of intensive consolidation therapy were administered to 13 patients with acute leukemia after they achieved complete remission. The patients were randomly allocated to receive their therapy in or out of a protected environment unit and with or without antibiotic prophylaxis. The results suggest that the protectedβenvironmentβprophylacticβantibiotic program may have protected the patients from infection, although the numbers in each group are too small for meaningful comparison. However, early consolidation therapy was not beneficial, since the duration of remission and survival of these patients was less than that of a group of comparable patients who received only conventional maintenance therapy.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND. Significant controversy surrounds the use of remission induction chemotherapy (IC) in older adults with acute myeloid leukemia (AML). Earlier clinical trials have yielded conflicting results and possibly a minor survival benefit, often offset by a longer hospitalization